Replies to post #2294 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA is due a $28.7M tax refund from the IRS relating to NOL carrybacks allowed by the 2020 Cares Act.

[DewDiligence]

FY3Q22* financials—9/30/22_pro_forma_cash=$307.2M (including $28.7M tax refund due from IRS):

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-33

FY4Q22 royalty revenue was $20.3M, up from $19.5M in FY2Q22 (#msg-169620050). FY2022* (12m) royalty revenue was $86.2M, down from $97.1M in FY2021.

FY2022 (12m) R&D expenses were $164.5M, inline with ENTA’s guidance of $150-170M. FY2022 (12m) SG&A expenses were $45.5M, slightly above ENTA’s guidance of $35-41M.

For FY2023*, ENTA today issued guidance of $210-230M of R&D expenses and $46-52M of SG&A expenses.

*ENTA’s fiscal years end on September 30.